Participation of trypanothione in clinical and experimental Sb resistance in L.
Antimonials have been the first line treatment for all clinical forms of leishmaniasis for over 60 years (30) . Treatment failure increasingly challenges the effective management of leishmaniasis (1, 19, 23, 29) . Proof for selection of resistant populations of Leishmania during treatment and prospective demonstration of a causal link between treatment failure and drug resistant Leishmania have recently been established with clinical isolates of the Viannia subgenus (26) .
The mechanisms of action of antimonials remain uncertain, however it is generally considered that pentavalent antimony (Sb V ) is a prodrug that is reduced to the active trivalent form (Sb III ). This reductive activation evidently occurs inside both the parasite and host macrophages (25, 27, 28) . While down-regulation of the genes encoding TDR1, AQP1, and ACR2 confers resistance to Sb III in vitro (12, 15, 30) , the best known mechanism of experimental resistance to Sb involves detoxification of Sb III via conjugation to trypanothione (T[SH] 2 ) (13, 14, 18) .
Overproduction of T[SH] 2 results
from enhanced capacity of the parasite to produce the precursors of T[SH] 2 ; glutathione (GSH) and spermidine, mediated respectively by amplification of the gsh1 gene, encoding γ-glutamylcysteine-synthetase (γGCS) and by transcriptional over-expression of ornithine decarboxylase (ODC) (16, 17, 21 values were compared using the Duncan test. P values of < 0.05 were considered significant. Statistical analyses were performed on data from at least 3 independent and 86% when treated with 5 mM BSO, DFMO and BSO+DFMO respectively ( Figure   1B ); P<0.02 for BSO and BSO+DFMO versus Sb III treatment alone. µg/ml ± SE 0.20) and BSO+DFMO (4.7 µg/ml ± SE 0.15) (P<0.009) Figure 1A , Table 2 .
A C C E P T E D

Strains isolated at relapse and resistant to Sb V as intracellular amastigotes, were as susceptible to Sb III as promastigotes of the pretreatment Sb V sensitive strain ( Table 2 ). Figure 1C ). DFMO did not significantly increase the toxicity of Sb V . ED 50 of Sb V for macrophages was 858.9 ugSb/mL. (I) at diagnosis, (R1) first relapse, (R2) second relapse. 
